☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Johnson & Johnson
Johnson & Johnson’s Edurant Receives the EC Approval for Expanded Use as HIV-1 Therapy in Pediatric Individuals
October 30, 2024
Johnson & Johnson Reports Tremfya Pooled Analysis from GALAXI-2, 3 and QUASAR Trials
October 11, 2024
Johnson & Johnson Completes the Acquisition of V-Wave
October 11, 2024
Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate C...
October 3, 2024
Johnson & Johnson Submits sBLA of Darzalex Faspro Regimen to the US FDA for Newly Diagnosed Multiple Myeloma Patients
October 1, 2024
Johnson & Johnson Reports the US FDA’s Approval of Rybrevant Plus Standard of Care to Treat EGFR-Mutated NSCLC
September 20, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.